Arkolith/Insider Trading/GTBP/Form 4

Breen Michael Martin

Executive Chairman/Interim CEO, DirectorGT Biopharma, Inc. (GTBP) · full profile →Form 4 · filed Apr 11, 2023
Net Buying
Open-Market Buys
$25K
Open-Market Sells
$0
Net Open-Market Flow
$25K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 11, 2023Buy(P)50K$0.50$25K656K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-23-011888) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML